HCA HCA Healthcare, Inc. Common Stock
HCA Healthcare, Inc. Common Stock 정보 위키백과 회사 개요
HCA Healthcare, Inc. is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
더 보기
HCA Healthcare, Inc. (historically known as Hospital Corporation of America) is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
History
Early years
The Hospital Corporation of America (HCA) was founded in 1968 in Nashville, Tennessee, by Thomas F. Frist Sr., Thomas F. Frist Jr. and Jack C. Massey. The founders envisioned a company that would bring together hospitals to deliver patient-focused care while using the combined resources of the organization to strengthen hospitals and improve the practice of medicine. The company began with Nashville's Park View Hospital, which the elder Frist had founded in 1960 with other doctors and where he was serving as chief executive.
The company included 11 hospitals when it filed its initial public offering on the New York Stock Exchange (NYSE) in 1969 and had 26 hospitals and 3,000 beds by the end of the year.
Growth and merger
The 1970s were characterized by rapid growth in the industry and for HCA Healthcare. In the early 1980s, the focus shifted to consolidation with HCA Healthcare acquiring General Care Corporation, General Health Services, Hospital Affiliates International and Health Care Corporation. By the end of 1981, the company operated 349 hospitals with more than 49,000 beds. Operating revenues had grown to $2.4 billion.
In 1987, HCA Healthcare, which had grown to operate 463 hospitals (255 owned and 208 managed), spun off HealthTrust, a privately owned, 104-hospital company. Believing its stock was undervalued, the company completed a $5.1 billion leveraged management buyout led by chairman Thomas F. Frist Jr. in 1988. HCA Healthcare re-emerged as a public company in 1992.
In February 1994, HCA Healthcare merged with Louisville, Kentucky-based Columbia Hospital Corporation, which earlier had acquired 73 hospitals of Galen Health Care from Humana,
to form Columbia/HCA Healthcare Corporation. Related names of note include HCA International and Health Corporation of America.
Columbia Hospital Corporation
In 1988, Rick Scott and Richard Rainwater each put up $125,000 in working capital in their new company, Columbia Hospital Corporation; they borrowed the remaining money needed to purchase two struggling hospitals in El Paso for $60 million. Then they acquired a neighboring hospital and shut it down. Within a year, the remaining two were doing much better. By the end of 1989, Columbia Hospital Corporation owned four hospitals with a total of 833 beds.
In 1992, Columbia made a stock purchase of Basic American Medical, which owned eight hospitals, primarily in southwestern Florida. In September 1993, Columbia did another stock purchase, worth $3.4 billion, of Galen Healthcare, which had been spun off by Humana Inc. several months earlier. At the time, Galen had approximately 90 hospitals. After the purchase, Galen stockholders had 82% of the stock in the combined company, with Scott still running the company.
Recent history
On November 17, 2006, HCA became a private company for the third time when it completed a merger in which the company was acquired by a private investor group including affiliates of Kohlberg Kravis Roberts and Bain Capital, together with Merrill Lynch and HCA Healthcare founder Thomas F. Frist Jr. The total transaction was valued at approximately $33 billion, making it the largest leveraged buyout in history at the time, eclipsing the 1989 buyout of RJR Nabisco.
In May 2010, HCA announced that the corporation would once again go public with an expected $4.6-billion IPO as HCA Holdings, Inc. In March 2011, HCA sold 126.2 million shares for $30 each, raising about $3.79 billion, at that time, the largest private-equity backed IPO in U.S. history. In May 2017, the corporation was renamed HCA Healthcare.
In December 2018, a historical marker was installed in the parking lot of HCA's Sarah Cannon Cancer Center in Nashville, formerly the location of HCA's first hospital, Park View Hospital.
In 2018, the company was ranked No. 67 in the 2019 Fortune 500 list of the largest United States corporations by total revenue.
In May 2021, the company finalized a deal with Google to develop healthcare algorithms using patient records. In August 2021, HCA announced a deal with venture capital firm General Catalyst to develop digital solutions to streamline workflows and improve patient care; as part of the deal, HCA sold its healthcare app development firm PatientKeeper to General Catalyst's portfolio company Commure.
In April 2022, HCA Healthcare announced a $1.5 million partnership with Florida International University's Nicole Wertheim college of Nursing and Health Sciences, to expand its facilities to address the national nursing shortage.
In October 2022, LCMC Health in partnership with Tulane University announced that it would acquire Tulane Medical Center, Lakeview Regional Medical Center, and Tulane Lakeside Hospital from HCA for $150 million pending regulatory approval.
In March 2024, it was announced HCA had completed the sale of West Hills Hospital and Medical Center and related assets in Los Angeles, California to UCLA Health, for an undisclosed amount.
Facilities
United States
As of 2024, HCA has 186 hospitals. They also report operating more than 2,400 additional sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics located in 20 U.S. states and in the United Kingdom. A significant portion of those hospitals are situated in Florida and Texas. As of 2022, HCA had 47 hospitals and 31 surgery centers in Florida, and 45 hospitals and 632 affiliated sites of care in Texas. In 2021, it announced plans to build 3 new hospitals in Florida. In 2022, The Dallas Morning News reported that HCA will build 5 new hospitals in Texas. They also have a strong presence in Tennessee, where it began. HCA had 13 hospitals there as of 2019.
Between 2003 and 2017, HCA did not enter any new markets. However, in July 2007, HCA sold its hospitals in Switzerland.
In 2017, HCA acquired the Memorial University Medical Center in Savannah, Georgia. That same year, they acquired three Houston, Texas, hospitals from Tenet Healthcare.
In 2019 they purchased Mission Health System which operates hospitals in North Carolina.
In January 2020, HCA Healthcare acquired Valify, a healthcare cost-management company. In May 2020, HCA acquired 49-bed Shands Starke (Fla.) Regional Medical Center and 25-bed Shands Live Oak (Fla.) Regional Medical Center from CHS. HCA is operating the two facilities as off-campus emergency departments of Lake City (Fla.) Medical Center and North Florida Regional Medical Center in Gainesville. Later that year, it signed an agreement to sell Garden Park Medical Center to Singing River Health System.
In 2021, HCA sold Redmond Regional Medical Center to AdventHealth for $635M, and four other Georgia hospitals to Piedmont Healthcare for $950 million. They also announced the acquisition of Meadows Regional Medical Center.
United Kingdom
HCA International, the UK arm of Hospital Corporation of America, "caters for around half of all private patients in London." The main hospital sites within the United Kingdom it operates include:
It opened urgent care walk-in centres at London Bridge Hospital and the Portland Hospital in March 2018. It claims that patients, on average, wait just seven minutes to see a nurse and 17 minutes to see a doctor. In February 2022, outsourced cleaning staff at London Bridge Hospital reported a lack of PPE, no access to sick pay, a lack of training and no prior warning about which rooms may be contaminated with the virus through the COVID-19 pandemic.
The Princess Grace Hospital specializes in breast cancer and surgery, aided by Kefah Mokbel and Nick Perry who, in 2005, founded The London Breast Institute.
The company opened The Harborne Hospital, a newly built private hospital located close to the Queen Elizabeth Hospital, Birmingham, in February 2024.
Significant areas of operation
Medical education
In recent years, HCA Healthcare has become a significant provider of clinical and medical education. It is the largest sponsor of graduate medical education programs in the U.S., with 56 teaching hospitals in 14 states, primarily in regions with a deficit of physician training programs. The company includes Research College of Nursing and Mercy School of Nursing, and has several advanced nursing simulation training centers. In early 2020, it completed the purchase of a majority stake in Galen College of Nursing, which operates 21 campuses in 12 states, offering Bachelor of Science and Associate of Science nursing degrees.
Controversies
Medicare billing practices lawsuit
In 1993, lawsuits were filed against HCA by former employees who alleged that the company had engaged in questionable Medicare billing practices. In 1997, with a federal investigation by the FBI, the IRS and the Department of Health and Human Services in its early stages, the Columbia/HCA board of directors forced Rick Scott to resign as chairman and CEO amid growing evidence that the company "had kept two sets of books, one to show the government and one with actual expenses listed." Thomas Frist, a co-founder of HCA and brother of U.S. Senator Bill Frist, returned to the company as CEO in 1997 and called on longtime friend and colleague Jack O. Bovender Jr. to help him turn the company around.
The federal probe culminated in 2003 with "the government receiving a total of over $2 billion in criminal fines and civil penalties for systematically defrauding federal health care programs." Columbia/HCA pleaded guilty to 14 felonies and admitted to systematically overcharging the government. The federal probe has been referred to as the longest and costliest investigation for health-care fraud in U.S. history.
2005 insider trading suit
In July 2005, U.S. Senator Bill Frist sold all of his HCA shares, which were held in a blind trust, two weeks before disappointing earnings sent the stock on a 9-point plunge. At the time, Frist was considering a run for president and said that he had sold his shares to avoid the appearance of a conflict of interest. When the company disclosed that other executives had also sold their shares during that same time, shareholders alleged that the company had made false claims about its profits to drive up the price, which then fell when the company reported disappointing financial results. Eleven of HCA's senior officers were sued for accounting fraud and insider trading. HCA settled the lawsuit in August 2007, agreeing to pay $20 million to the shareholders but admitting no wrongdoing, and no charges were brought.
COVID-19 PPE
During the COVID-19 pandemic in the United States, HCA hospital nurses and other workers spoke out about the lack of PPE. In April 2020, there was an outcry against HCA following the deaths of two nurses Celia Yap-Banago and Rosa Luna who worked at HCA hospitals in Kansas City and California and had contracted coronavirus, despite the alarm having been raised about the lack of PPE at work.
Mission Hospital Acquisition Complaints
On December 14, 2023, the North Carolina Attorney General sued HCA for violating the terms of an agreement that allowed HCA to purchase Mission Health.
On February 13, 2024, HCA Healthcare denied the allegations and asked a judge to dismiss the lawsuit by the Attorney General, and in return the hospital network filed a counterclaim against the Attorney General.
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
HCA 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
HCA 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
10년 성과 매출, 순이익, 마진 및 EPS 추세
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
배당금 배당 수익률, 지급 비율, 배당 이력, 5년 CAGR
| 배당락일 | 금액 |
|---|---|
| 2026년 6월 16일 | $0.7800 |
| 2026년 3월 17일 | $0.7800 |
| 2025년 12월 15일 | $0.7200 |
| 2025년 9월 16일 | $0.7200 |
| 2025년 6월 16일 | $0.7200 |
| 2025년 3월 17일 | $0.7200 |
| 2024년 12월 13일 | $0.6600 |
| 2024년 9월 16일 | $0.6600 |
| 2024년 6월 14일 | $0.6600 |
| 2024년 3월 14일 | $0.6600 |
| 2023년 12월 13일 | $0.6000 |
| 2023년 9월 14일 | $0.6000 |
| 2023년 6월 15일 | $0.6000 |
| 2023년 3월 16일 | $0.6000 |
| 2022년 12월 13일 | $0.5600 |
| 2022년 9월 15일 | $0.5600 |
| 2022년 6월 15일 | $0.5600 |
| 2022년 3월 16일 | $0.5600 |
| 2021년 12월 13일 | $0.4800 |
| 2021년 9월 15일 | $0.4800 |
HCA 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
- 적극 매수 6 20.0%
- 매수 11 36.7%
- 보유 12 40.0%
- 매도 1 3.3%
- 적극 매도 0 0.0%
12개월 목표 주가
21 명의 애널리스트 · 2026-08-17실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
| 기간 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|
| 2026년 6월 30일 | $7.62 | $7.54 | 0.08% |
| 2026년 3월 31일 | $7.15 | $7.21 | -0.06% |
| 2025년 12월 31일 | $8.14 | $7.53 | 0.61% |
| 2025년 9월 30일 | $6.96 | $5.77 | 1.2% |
| 2025년 6월 30일 | $6.83 | $6.31 | 0.52% |
| 2025년 3월 31일 | $6.45 | $5.84 | 0.61% |
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| HCA | $104.86B | 16.5 | 7.1% | 9.0% | -159.1% | — |
| THC | $17.28B | 12.8 | 3.1% | 11.1% | 56.4% | — |
| EHC | $10.61B | 19.2 | 10.5% | 9.5% | 25.1% | — |
| ENSG | $10.12B | 29.8 | 18.7% | 6.8% | 16.9% | — |
| UHS | — | 9.4 | 9.7% | 8.6% | 21.4% | — |
| PACS | $6.01B | 31.5 | 29.3% | 3.6% | 23.1% | — |
| CON | $2.53B | 15.1 | 13.9% | 7.7% | 49.8% | — |
| BKD | $2.57B | -9.6 | 2.2% | -8.2% | -313.2% | 26.2% |
| ACHC | $1.28B | -1.2 | 5.0% | -33.3% | -43.9% | — |
| SNDA | $612M | -7.7 | 25.2% | -18.6% | -197.2% | — |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서 12
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| SG&A Expense | $548M | $421M | $353M | $307M | $337M | $416M | $370M | $344M | $340M | $343M | |
| Operating Expenses | $65.77B | $62.08B | $57.26B | $51.65B | $48.92B | $46.10B | $46.09B | $41.34B | $39.23B | $36.68B | |
| Interest Expense | $2.25B | $2.06B | $1.94B | $1.74B | $1.57B | $1.58B | $1.82B | $1.75B | $1.69B | $1.71B | |
| Pretax Income | $9.83B | $8.52B | $7.71B | $8.58B | $9.83B | $5.43B | $5.24B | $5.33B | $4.38B | $4.81B | |
| Income Tax | $2.05B | $1.87B | $1.61B | $1.75B | $2.11B | $1.04B | $1.10B | $946M | $1.64B | $1.38B | |
| Net Income | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| EPS (Basic) | $28.70 | $22.27 | $19.25 | $19.43 | $21.52 | $11.10 | $10.27 | $10.90 | $6.12 | $7.53 | |
| EPS (Diluted) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 | |
| Shares (Basic) | 236,413,000 | 258,603,000 | 272,404,000 | 290,348,000 | 323,315,000 | 338,274,000 | 341,210,000 | 347,297,000 | 362,305,000 | 383,591,000 | |
| Shares (Diluted) | 239,495,000 | 261,806,000 | 276,412,000 | 294,666,000 | 328,752,000 | 343,605,000 | 348,226,000 | 355,303,000 | 372,221,000 | 395,851,000 | |
| EBITDA | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B |
대차대조표 22
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.04B | $1.93B | $935M | $908M | $1.45B | $1.79B | $621M | $502M | $732M | $646M | |
| Short-term Investments | · | · | · | · | · | $116M | $147M | $47M | $54M | $49M | |
| Receivables | $10.87B | $10.75B | $9.96B | $8.89B | $8.10B | $7.05B | $7.38B | $6.79B | $6.50B | $5.83B | |
| Inventory | $1.65B | $1.74B | $2.02B | $2.07B | $1.99B | $2.02B | $1.85B | $1.73B | $1.57B | $1.50B | |
| Other Current Assets | $2.22B | $1.99B | $2.01B | $1.78B | $2.01B | $1.46B | $1.35B | $1.19B | $1.17B | $1.11B | |
| Current Assets | $15.78B | $16.41B | $14.93B | $13.64B | $13.54B | $12.33B | $11.20B | $10.21B | $9.98B | $9.09B | |
| PP&E (Net) | $31.14B | $29.41B | $27.71B | $25.57B | $24.06B | $23.20B | $22.71B | $19.76B | $17.89B | $16.35B | |
| PP&E (Gross) | $66.28B | $62.51B | $58.55B | $54.76B | $51.35B | $49.32B | $47.23B | $42.97B | $40.08B | $37.05B | |
| Accum. Depreciation | $35.13B | $33.10B | $30.83B | $29.18B | $27.29B | $26.12B | $24.52B | $23.21B | $22.19B | $20.70B | |
| Other Non-current Assets | $255M | $230M | $184M | $298M | $598M | $546M | $480M | $690M | $710M | $1.07B | |
| Total Assets | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Accounts Payable | $4.66B | $4.28B | $4.23B | $4.24B | $4.11B | $3.54B | $2.90B | $2.58B | $2.61B | $2.32B | |
| Current Liabilities | $16.35B | $15.18B | $12.65B | $9.90B | $9.58B | $8.70B | $7.76B | $7.57B | $6.16B | $5.83B | |
| Capital Leases | $1.85B | $1.86B | $1.90B | $1.75B | $1.75B | $1.67B | $1.50B | · | · | · | |
| Total Liabilities | · | · | · | · | · | · | $45.62B | $42.12B | $41.59B | $39.39B | |
| Long-term Debt | $44.28B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Total Debt | $41.60B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Retained Earnings | $-5.72B | $-2.12B | $-1.35B | $-2.28B | $-532M | $777M | $-2.35B | $-4.57B | $-6.53B | $-6.97B | |
| AOCI | $-305M | $-387M | $-425M | $-490M | $-404M | $-502M | $-460M | $-381M | $-278M | $-338M | |
| Stockholders' Equity | $-6.03B | $-2.50B | $-1.77B | $-2.77B | $-933M | $572M | $-2.81B | $-4.95B | $-6.81B | $-7.30B | |
| Liabilities + Equity | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Shares Outstanding | 224,605,100 | 249,981,400 | 265,537,300 | 277,378,300 | 305,476,800 | 339,425,600 | 338,445,600 | 342,895,200 | 350,091,600 | 370,535,900 |
현금 흐름 17
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B | |
| Stock-based Comp | $401M | $360M | $262M | $341M | $440M | $362M | $347M | $268M | $270M | $251M | |
| Amort. of Intangibles | $12M | $16M | $20M | $44M | $25M | $26M | · | · | · | · | |
| Other Non-cash | $1.93B | $1.08B | $850M | $-431M | $-1.29B | $2.40B | $1.07B | $461M | $-3.53B | $-2.67B | |
| Operating Cash Flow | $12.64B | $10.51B | $9.43B | $8.52B | $8.96B | $9.23B | $7.60B | $6.76B | $5.43B | $5.65B | |
| CapEx | $4.94B | $4.88B | $4.74B | $4.39B | $3.58B | $2.83B | $4.16B | $3.57B | $3.02B | $2.76B | |
| Investing Cash Flow | $-4.99B | $-4.93B | $-5.32B | $-3.39B | $-2.64B | $-3.39B | $-5.72B | $-3.90B | $-4.28B | $-3.24B | |
| Debt Issued | $8.47B | $7.50B | $3.22B | $6.00B | $4.34B | $2.70B | $6.45B | $2.00B | $1.50B | $5.40B | |
| Net Debt Issued | $1.08B | $5.08B | $2.31B | $3.17B | $475M | $-737M | $1.13B | $296M | $749M | $925M | |
| Stock Repurchased | $10.07B | $6.04B | $3.81B | $7.00B | $8.21B | $441M | $1.03B | $1.53B | $2.05B | $2.75B | |
| Net Stock Activity | $-10.07B | $-6.04B | $-3.81B | $-7.00B | $-8.21B | $-441M | $-1.03B | $-1.53B | $-2.05B | $-2.75B | |
| Dividends Paid | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · | |
| Financing Cash Flow | $-8.55B | $-4.58B | $-4.09B | $-5.66B | $-6.66B | $-4.68B | $-1.77B | $-3.08B | $-1.06B | $-2.51B | |
| Net Change in Cash | $-893M | $998M | $27M | $-543M | $-342M | $1.17B | $119M | $-230M | $86M | $-95M | |
| Taxes Paid | $1.74B | $1.84B | $1.39B | $1.18B | $2.18B | $1.00B | $849M | $872M | $1.21B | $1.25B | |
| Free Cash Flow | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B | $6.40B | $3.44B | $3.19B | $2.41B | $2.89B | |
| Levered FCF | $5.91B | $4.03B | $3.16B | $2.74B | $4.15B | $5.12B | $2.00B | $1.74B | $1.35B | $1.68B |
수익성 5
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 9.0% | 8.2% | 8.1% | 9.4% | 11.8% | 7.3% | 6.8% | 8.1% | · | · | |
| Pretax Margin | 13.0% | 12.1% | 11.9% | 14.2% | 16.7% | 10.5% | 10.2% | 11.4% | · | · | |
| EBITDA Margin | 4.7% | 4.7% | 4.7% | 4.9% | 4.9% | 5.3% | 5.1% | 4.9% | · | · | |
| ROA | 11.3% | 10.0% | 9.7% | 10.9% | 14.2% | 8.1% | 8.3% | 10.0% | 6.3% | 8.7% | |
| ROE | -159.1% | -269.6% | -230.9% | -305.0% | -3853.7% | -335.8% | -90.4% | -64.4% | -31.4% | -38.8% |
유동성 및 지급능력 4
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.3 | 1.6 | 1.6 | |
| Quick Ratio | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 | 1.0 | 1.1 | 1.0 | 1.2 | 1.1 | |
| Debt / Equity | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 | 54.2 | -12.0 | -6.6 | -4.9 | -4.3 | |
| LT Debt / Equity | -6.9 | -15.3 | -21.0 | -13.6 | -36.8 | 53.8 | -12.0 | -6.5 | -4.8 | -4.3 |
효율성 2
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.3 | 1.2 | 1.2 | 1.2 | 1.2 | 1.1 | 1.2 | 1.2 | · | · | |
| Receivables Turnover | 7.0 | 6.8 | 6.9 | 7.1 | 7.8 | 7.1 | 7.2 | 7.0 | · | · |
성장률 10
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.1% | 8.7% | 7.9% | 2.5% | 14.0% | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.9% | 6.3% | 8.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.0% | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 28.8% | 16.0% | -0.94% | -9.5% | 93.6% | · | · | · | · | · | |
| EPS CAGR 3Y | 13.9% | 1.3% | 20.2% | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 21.0% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 17.8% | 9.9% | -7.1% | -18.9% | 85.3% | · | · | · | · | · | |
| Net Income CAGR 3Y | 6.3% | -6.1% | 11.8% | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 12.6% | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 34.7% | · | · | · | · | · | · | · | · | · |
가치 평가 (TTM) 17
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| Net Income TTM | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| Market Cap | $104.86B | $75.03B | $71.88B | $66.56B | $78.48B | $55.82B | $50.03B | $42.67B | $30.75B | $27.43B | |
| Enterprise Value | $145.42B | $116.13B | $110.53B | $103.74B | $111.61B | $84.92B | $82.98B | $74.95B | $63.02B | $58.11B | |
| P/E | 16.5 | 13.6 | 14.3 | 12.5 | 12.1 | 15.0 | 14.7 | 11.7 | 14.8 | 10.1 | |
| P/S | 1.4 | 1.1 | 1.1 | 1.1 | 1.3 | 1.1 | 1.0 | 0.9 | 0.7 | 0.7 | |
| P/B | -17.4 | -30.0 | -40.5 | -24.1 | -84.1 | 97.6 | -17.8 | -8.6 | -4.5 | -3.8 | |
| P / Tangible Book | · | · | · | · | · | 97.6 | · | · | · | · | |
| P / Cash Flow | 8.3 | 7.1 | 7.6 | 7.8 | 8.8 | 6.0 | 6.6 | 6.3 | 5.7 | 4.9 | |
| P / FCF | 13.6 | 13.3 | 15.3 | 16.1 | 14.6 | 8.7 | 14.5 | 13.4 | 12.8 | 9.5 | |
| EV / EBITDA | 41.3 | 35.1 | 35.9 | 34.9 | 39.1 | 31.2 | 32.0 | 32.9 | 29.6 | 29.6 | |
| EV / FCF | 18.9 | 20.6 | 23.6 | 25.1 | 20.7 | 13.3 | 24.1 | 23.5 | 26.1 | 20.1 | |
| EV / Revenue | 1.9 | 1.6 | 1.7 | 1.7 | 1.9 | 1.6 | 1.6 | 1.6 | 1.4 | 1.4 | |
| Dividend Yield | 0.65% | 0.92% | 0.92% | 0.98% | 0.80% | 0.27% | 1.1% | 1.1% | 0.00% | · | |
| Earnings Yield | 6.1% | 7.3% | 7.0% | 8.0% | 8.2% | 6.7% | 6.8% | 8.6% | 6.8% | 9.9% | |
| Payout Ratio | 10.0% | 12.0% | 12.6% | 11.6% | 9.0% | 4.1% | 15.7% | 12.9% | · | · | |
| Annual Payout | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · |
손익계산서 12
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.23B | $19.11B | $19.51B | $19.16B | $18.61B | $18.32B | $18.29B | $17.49B | $17.49B | $17.34B | $17.30B | $16.21B | $15.86B | $15.59B | $15.50B | $14.97B | |
| SG&A Expense | $148M | $133M | $153M | $139M | $130M | $126M | $120M | $111M | $100M | $90M | $108M | $89M | $82M | $74M | $79M | $74M | |
| Operating Expenses | $17.74B | $16.82B | $16.84B | $16.74B | $16.19B | $15.99B | $16.15B | $15.58B | $15.26B | $15.09B | $14.96B | $14.58B | $14.05B | $13.67B | $12.20B | $13.27B | |
| Interest Expense | $599M | $584M | $572M | $561M | $568M | $547M | $528M | $515M | $506M | $512M | $491M | $483M | $485M | $479M | $453M | $446M | |
| Pretax Income | $2.49B | $2.29B | $2.67B | $2.42B | $2.42B | $2.33B | $2.13B | $1.91B | $2.24B | $2.25B | $2.35B | $1.63B | $1.81B | $1.92B | $3.30B | $1.70B | |
| Income Tax | $564M | $430M | $509M | $515M | $524M | $502M | $447M | $424M | $550M | $445M | $484M | $355M | $397M | $379M | $656M | $360M | |
| Net Income | $1.70B | $1.62B | $1.88B | $1.64B | $1.65B | $1.61B | $1.44B | $1.27B | $1.46B | $1.59B | $1.61B | $1.08B | $1.19B | $1.36B | $2.08B | $1.13B | |
| EPS (Basic) | $7.70 | $7.25 | $8.22 | $7.05 | $6.91 | $6.52 | $5.72 | $4.94 | $5.60 | $6.01 | $6.00 | $3.98 | $4.35 | $4.92 | $7.30 | $3.97 | |
| EPS (Diluted) | $7.62 | $7.15 | $8.09 | $6.96 | $6.83 | $6.45 | $5.66 | $4.88 | $5.53 | $5.93 | $5.92 | $3.91 | $4.29 | $4.85 | $7.20 | $3.91 | |
| Shares (Basic) | 220,538,000 | 223,588,000 | -482,587,000 | 232,891,000 | 239,173,000 | 246,936,000 | -523,751,000 | 256,763,000 | 261,156,000 | 264,435,000 | -550,173,000 | 271,173,000 | 274,494,000 | 276,910,000 | -590,583,000 | 285,958,000 | |
| Shares (Diluted) | 222,828,000 | 226,652,000 | -488,037,000 | 236,181,000 | 241,911,000 | 249,440,000 | -530,198,000 | 259,917,000 | 264,071,000 | 268,016,000 | -558,171,000 | 275,424,000 | 278,198,000 | 280,961,000 | -598,621,000 | 289,852,000 | |
| EBITDA | $944M | $930M | · | $889M | $863M | $860M | · | $842M | $819M | $795M | · | $769M | $763M | $756M | · | $749M |
대차대조표 20
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.01B | $940M | $1.04B | $997M | $939M | $1.06B | $1.93B | $2.89B | $831M | $1.28B | · | $891M | $862M | $842M | · | $999M | |
| Receivables | $12.28B | $11.32B | $10.87B | $10.43B | $10.46B | $11.09B | $10.75B | $9.91B | $10.24B | $10.04B | · | $9.18B | $8.71B | $8.66B | · | $8.55B | |
| Inventory | $1.66B | $1.68B | $1.65B | $1.73B | $1.79B | $1.79B | $1.74B | $1.78B | $1.80B | $1.90B | · | $2.03B | $2.05B | $2.08B | · | $2.01B | |
| Other Current Assets | $2.23B | $2.11B | $2.22B | $2.13B | $2.37B | $2.32B | $1.99B | $2.08B | $2.30B | $2.05B | · | $2.19B | $2.26B | $1.96B | · | $1.92B | |
| Current Assets | $17.19B | $16.05B | $15.78B | $15.29B | $15.56B | $16.26B | $16.41B | $16.66B | $15.17B | $15.28B | · | $14.29B | $13.89B | $13.54B | · | $13.48B | |
| PP&E (Net) | $31.82B | $31.47B | $31.14B | $30.57B | $30.12B | $29.74B | $29.41B | $29.05B | $28.64B | $28.10B | · | $27.12B | $26.64B | $26.05B | · | $24.98B | |
| PP&E (Gross) | $68.41B | $67.36B | $66.28B | $65.49B | $64.39B | $63.68B | $62.51B | $61.75B | $60.62B | $59.44B | · | $57.77B | $56.67B | $55.46B | · | $53.73B | |
| Accum. Depreciation | $36.59B | $35.89B | $35.13B | $34.92B | $34.27B | $33.94B | $33.10B | $32.70B | $31.99B | $31.34B | · | $30.66B | $30.02B | $29.41B | · | $28.75B | |
| Other Non-current Assets | $258M | $326M | $255M | $277M | $236M | $226M | $230M | $309M | $240M | $199M | · | $200M | $196M | $319M | · | $461M | |
| Total Assets | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | $56.21B | $54.59B | $53.59B | $52.71B | $52.44B | $51.48B | |
| Accounts Payable | $4.75B | $4.81B | $4.66B | $4.55B | $4.25B | $4.49B | $4.28B | $4.24B | $4.03B | $4.74B | · | $4.14B | $3.82B | $3.77B | · | $4.16B | |
| Current Liabilities | $17.31B | $19.26B | $16.35B | $17.90B | $15.94B | $13.63B | $15.18B | $14.90B | $14.30B | $13.14B | · | $12.41B | $11.54B | $11.03B | · | $9.78B | |
| Capital Leases | $1.83B | $1.82B | $1.85B | $1.84B | $1.88B | $1.86B | $1.86B | $1.92B | $1.89B | $1.91B | · | $1.78B | $1.81B | $1.72B | · | $1.76B | |
| Long-term Debt | $45.83B | $44.37B | $44.28B | $42.60B | $42.70B | $44.58B | $43.03B | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Total Debt | $43.45B | $39.49B | · | $38.40B | $39.38B | $44.58B | · | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Retained Earnings | $-6.31B | $-5.98B | $-5.72B | $-5.02B | $-4.09B | $-3.16B | $-2.12B | $-1.81B | $-1.17B | $-1.19B | · | $-1.99B | $-1.85B | $-2.03B | · | $-2.78B | |
| AOCI | $-334M | $-327M | $-305M | $-317M | $-309M | $-357M | $-387M | $-378M | $-433M | $-433M | $-425M | $-491M | $-456M | $-470M | $-490M | $-592M | |
| Stockholders' Equity | $-6.64B | $-6.30B | $-6.03B | $-5.33B | $-4.39B | $-3.52B | $-2.50B | $-2.18B | $-1.60B | $-1.61B | · | $-2.48B | $-2.30B | $-2.50B | · | $-3.37B | |
| Liabilities + Equity | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | · | $54.59B | $53.59B | $52.71B | · | $51.48B | |
| Shares Outstanding | 217,963,300 | 222,530,900 | 224,605,100 | 229,845,100 | 236,143,900 | 242,955,400 | 249,981,400 | 254,517,700 | 259,237,600 | 263,215,800 | · | 268,967,300 | 272,931,700 | 275,939,900 | · | 283,903,500 |
현금 흐름 16
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $944M | $930M | $911M | $889M | $863M | $860M | $856M | $842M | $819M | $795M | $789M | $769M | $763M | $756M | $750M | $749M | |
| Stock-based Comp | $85M | $86M | $100M | $104M | $99M | $98M | $85M | $76M | $112M | $87M | $57M | $72M | $56M | $77M | $83M | $87M | |
| Other Non-cash | · | $-622M | · | · | · | $-917M | · | · | · | $-4M | · | · | · | $-393M | · | · | |
| Operating Cash Flow | $2.33B | $2.01B | $2.36B | $4.42B | $4.21B | $1.65B | $2.56B | $3.52B | $1.97B | $2.47B | $2.67B | $2.48B | $2.48B | $1.80B | $2.53B | $3.02B | |
| CapEx | $1.23B | $1.12B | $1.49B | $1.29B | $1.18B | $991M | $1.28B | $1.19B | $1.28B | $1.12B | $1.16B | $1.15B | $1.24B | $1.20B | $1.32B | $1.13B | |
| Investing Cash Flow | $-1.56B | $-1.28B | $-1.32B | $-1.39B | $-1.25B | $-1.03B | $-1.35B | $-1.35B | $-1.33B | $-903M | $-1.60B | $-1.31B | $-1.26B | $-1.15B | $-793M | $-546M | |
| Debt Issued | $2.99B | $0 | $3.24B | $0 | $0 | $5.23B | $0 | $3.01B | $0 | $4.48B | $4M | $2M | $3.22B | $0 | $21M | $10M | |
| Net Debt Issued | · | $-58M | · | · | · | $1.34B | · | · | · | $2.42B | · | · | · | $-550M | · | · | |
| Stock Repurchased | $2.06B | $1.57B | $2.56B | $2.50B | $2.50B | $2.51B | $1.70B | $1.79B | $1.37B | $1.18B | $910M | $1.14B | $915M | $846M | $1.52B | $698M | |
| Net Stock Activity | · | $-1.57B | · | · | · | $-2.51B | · | · | · | $-1.18B | · | · | · | $-846M | · | · | |
| Dividends Paid | $171M | $183M | $162M | $166M | $171M | $180M | $165M | $169M | $171M | $185M | $160M | $162M | $164M | $175M | $156M | $160M | |
| Financing Cash Flow | $-704M | $-830M | $-999M | $-2.97B | $-3.09B | $-1.50B | $-2.16B | $-110M | $-1.09B | $-1.22B | $-1.04B | $-1.13B | $-1.20B | $-725M | $-1.84B | $-2.32B | |
| Net Change in Cash | $73M | $-100M | $43M | $58M | $-121M | $-873M | $-955M | $2.06B | $-453M | $349M | $44M | $29M | $20M | $-66M | $-91M | $141M | |
| Taxes Paid | $730M | $-5M | $1.51B | $81M | $136M | $10M | $358M | $487M | $998M | $1M | $316M | $297M | $766M | $7M | $244M | $322M | |
| Free Cash Flow | · | $895M | · | · | · | $660M | · | · | · | $1.35B | · | · | · | $606M | · | · | |
| Levered FCF | · | $421M | · | · | · | $231M | · | · | · | $940M | · | · | · | $221M | · | · |
수익성 5
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 8.4% | 8.5% | · | 8.6% | 8.9% | 8.8% | · | 7.3% | 8.3% | 9.2% | · | 6.7% | 7.5% | 8.7% | · | 7.6% | |
| Pretax Margin | 12.3% | 12.0% | · | 12.6% | 13.0% | 12.7% | · | 10.9% | 12.8% | 13.0% | · | 10.1% | 11.4% | 12.3% | · | 11.4% | |
| EBITDA Margin | 4.7% | 4.9% | · | 4.6% | 4.6% | 4.7% | · | 4.8% | 4.7% | 4.6% | · | 4.7% | 4.8% | 4.9% | · | 5.0% | |
| ROA | 2.8% | 2.7% | · | 2.8% | 2.8% | 2.8% | · | 2.2% | 2.6% | 2.9% | · | 2.0% | 2.3% | 2.6% | · | 2.2% | |
| ROE | -30.8% | -33.0% | · | -43.7% | -55.2% | -62.7% | · | -54.5% | -74.9% | -77.4% | · | -36.9% | -39.9% | -60.2% | · | -55.8% |
유동성 및 지급능력 4
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 0.8 | · | 0.9 | 1.0 | 1.2 | · | 1.1 | 1.1 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.4 | |
| Quick Ratio | 0.8 | 0.6 | · | 0.6 | 0.7 | 0.9 | · | 0.9 | 0.8 | 0.9 | · | 0.8 | 0.8 | 0.9 | · | 1.0 | |
| Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -12.7 | · | -19.7 | -25.6 | -24.9 | · | -15.9 | -16.9 | -15.6 | · | -11.2 | |
| LT Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -11.7 | · | -17.5 | -22.7 | -23.0 | · | -14.9 | -15.9 | -14.6 | · | -11.1 |
효율성 2
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | |
| Receivables Turnover | 1.8 | 1.7 | · | 1.9 | 1.8 | 1.7 | · | 1.8 | 1.8 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
가치 평가 (TTM) 14
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $77.11B | $75.20B | · | $73.57B | $71.91B | $70.64B | · | $68.53B | $66.91B | $65.00B | · | $62.64B | $61.24B | $60.33B | · | $60.01B | |
| Net Income TTM | $6.62B | $6.53B | · | $6.18B | $5.99B | $5.93B | · | $5.40B | $5.32B | $5.23B | · | $4.77B | $4.84B | $4.92B | · | $5.83B | |
| Market Cap | $84.98B | $105.31B | · | $97.96B | $90.47B | $83.95B | · | $103.44B | $83.29B | $87.79B | · | $66.16B | $82.83B | $72.76B | · | $52.18B | |
| Enterprise Value | $127.42B | $143.86B | · | $135.36B | $128.91B | $127.47B | · | $143.52B | $123.34B | $126.70B | · | $104.62B | $120.90B | $110.77B | · | $88.89B | |
| P/E | 13.7 | 17.3 | · | 17.0 | 16.2 | 15.2 | · | 20.1 | 16.3 | 17.6 | · | 14.5 | 17.9 | 15.7 | · | 9.7 | |
| P/S | 1.1 | 1.4 | · | 1.3 | 1.3 | 1.2 | · | 1.5 | 1.2 | 1.4 | · | 1.1 | 1.4 | 1.2 | · | 0.9 | |
| P/B | -12.8 | -16.7 | · | -18.4 | -20.6 | -23.9 | · | -47.4 | -52.1 | -54.4 | · | -26.7 | -36.0 | -29.2 | · | -15.5 | |
| P / Cash Flow | · | 52.3 | · | · | · | 50.8 | · | · | · | 35.6 | · | · | · | 40.4 | · | · | |
| P / FCF | · | 117.7 | · | · | · | 127.2 | · | · | · | 65.0 | · | · | · | 120.1 | · | · | |
| EV / EBITDA | 135.0 | 154.7 | · | 152.3 | 149.4 | 148.2 | · | 170.5 | 150.6 | 159.4 | · | 136.0 | 158.5 | 146.5 | · | 118.7 | |
| EV / FCF | · | 160.7 | · | · | · | 193.1 | · | · | · | 93.8 | · | · | · | 182.8 | · | · | |
| EV / Revenue | 1.7 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.1 | 1.8 | 1.9 | · | 1.7 | 2.0 | 1.8 | · | 1.5 | |
| Earnings Yield | 7.3% | 5.8% | · | 5.9% | 6.2% | 6.6% | · | 5.0% | 6.1% | 5.7% | · | 6.9% | 5.6% | 6.4% | · | 10.3% | |
| Payout Ratio | · | 11.3% | · | · | · | 11.2% | · | · | · | 11.6% | · | · | · | 12.8% | · | · |
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
손익계산서
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 매출 | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B |
| 순이익 | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B |
| 희석 EPS | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 |
대차대조표
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 부채 / 자기자본 비율 | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 |
| 유동비율 | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 |
| 당좌 비율 | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 |
현금 흐름
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 잉여현금흐름 | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B |
최신 뉴스 이 회사 관련 최근 헤드라인
- Could HCA Healthcare, Inc. (HCA) Stock Rebound After Guidance Cuts and Payer Pressure?
- Bernstein Remains Bullish On HCA Healthcare (HCA); Projects EBITDA Growth Of 2.8% and 4.6% in 2026 And 2027
- HCA Healthcare (HCA) Reports Q1 2026 Financial Growth With $19.1B in Revenue
- 주목할 만한 목요일 옵션 활동: HCA, HRTG, ZM
- HCA Healthcare (HCA) 자금 조달 전략 확장 – 방법은 다음과 같습니다.
- HCA Healthcare, 분기 이익 추정치 상회, 의료 서비스 수요 증가에 힘입어
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
기관 투자자 (13F) 1,491개의 제출자 · $39.4B 전체 · 기준일 2026년 6월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 128 (-51 이전 분기 대비) | 174 (+70 이전 분기 대비) | 450 (-30 이전 분기 대비) | 555 (-4 이전 분기 대비) | +16.3M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6,118,113,464 | 13,104,814 | 15.52% | 주식 |
| VANGUARD CAPITAL MANAGEMENT LLC | $3,954,150,533 | 10,141,708 | 10.03% | 주식 |
| Sanders Capital, LLC | $3,442,060,818 | 8,828,287 | 8.73% | 주식 |
| STATE STREET CORP | $2,912,102,056 | 7,469,035 | 7.39% | 주식 |
| WELLINGTON MANAGEMENT GROUP LLP | $1,750,298,867 | 4,489,212 | 4.44% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $1,225,259,672 | 3,159,159 | 3.11% | 주식 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1,057,704,509 | 2,712,828 | 2.68% | 주식 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $861,456,107 | 2,209,485 | 2.18% | 주식 |
| NORGES BANK | $836,457,140 | 2,145,367 | 2.12% | 주식 |
| Capital World Investors | $770,864,224 | 1,977,121 | 1.96% | 주식 |
| Capital International Investors | $747,403,041 | 1,916,947 | 1.90% | 주식 |
| Crake Asset Management LLP | $449,072,183 | 1,151,792 | 1.14% | 주식 |
| Metropolis Capital Ltd | $430,915,307 | 910,564 | 1.09% | 주식 |
| Darsana Capital Partners LP | $428,879,000 | 1,100,000 | 1.09% | 주식 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $414,533,777 | 1,063,207 | 1.05% | 주식 |
| Life Cycle Investment Partners Ltd | $355,737,196 | 912,404 | 0.90% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $339,685,814 | 871,235 | 0.86% | 주식 |
| FMR LLC | $325,199,295 | 834,080 | 0.82% | 주식 |
| BARCLAYS PLC | $299,888,573 | 769,162 | 0.76% | 주식 |
| LYRICAL ASSET MANAGEMENT LP | $255,015,742 | 654,071 | 0.65% | 주식 |
| BlackRock, Inc. | $240,062,291 | 615,718 | 0.61% | 주식 |
| ROYAL LONDON ASSET MANAGEMENT LTD | $235,649,908 | 604,401 | 0.60% | 주식 |
| National Pension Service | $230,650,346 | 591,578 | 0.59% | 주식 |
| NORDEA INVESTMENT MANAGEMENT AB | $230,189,125 | 594,466 | 0.58% | 주식 |
| GOLDMAN SACHS GROUP INC | $209,775,669 | 538,038 | 0.53% | 주식 |
| Gobi Capital LLC | $195,742,325 | 502,045 | 0.50% | 주식 |
| Cryder Capital Partners LLP | $194,561,738 | 499,017 | 0.49% | 주식 |
| Swiss National Bank | $172,097,446 | 441,400 | 0.44% | 주식 |
| AustralianSuper Pty Ltd | $159,635,782 | 409,438 | 0.40% | 주식 |
| Consulta Ltd | $155,956,000 | 400,000 | 0.40% | 주식 |
| LEE DANNER & BASS INC | $152,150,679 | 390,240 | 0.39% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $151,472,265 | 388,500 | 0.38% | 콜 옵션 |
| Mitsubishi UFJ Asset Management Co., Ltd. | $147,943,761 | 379,450 | 0.38% | 주식 |
| DIMENSIONAL FUND ADVISORS LP | $139,697,405 | 358,300 | 0.35% | 주식 |
| Vanguard Global Advisers, LLC | $136,962,509 | 351,285 | 0.35% | 주식 |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $134,838,505 | 288,820 | 0.34% | 주식 |
| ALLIANCEBERNSTEIN L.P. | $134,459,788 | 284,126 | 0.34% | 주식 |
| Sumitomo Mitsui Trust Group, Inc. | $132,794,974 | 340,596 | 0.34% | 주식 |
| TD Asset Management Inc | $131,847,152 | 338,165 | 0.33% | 주식 |
| Legal & General Group Plc | $127,805,162 | 327,798 | 0.32% | 주식 |
| California Public Employees Retirement System | $124,133,958 | 318,382 | 0.31% | 주식 |
| LAZARD ASSET MANAGEMENT LLC | $120,619,879 | 309,369 | 0.31% | 주식 |
| JANE STREET GROUP, LLC | $119,540,274 | 306,600 | 0.30% | 콜 옵션 |
| VANGUARD ASSET MANAGEMENT, Ltd | $116,069,863 | 297,699 | 0.29% | 주식 |
| CAPTRUST FINANCIAL ADVISORS | $114,741,071 | 294,291 | 0.29% | 주식 |
| ANTIPODES PARTNERS Ltd | $113,045,096 | 289,941 | 0.29% | 주식 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $109,718,328 | 231,845 | 0.28% | 주식 |
| CITADEL ADVISORS LLC | $105,660,190 | 271,000 | 0.27% | 콜 옵션 |
| RHUMBLINE ADVISERS | $97,580,413 | 250,277 | 0.25% | 주식 |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $97,026,076 | 248,855 | 0.25% | 주식 |
| MACKENZIE FINANCIAL CORP | $93,597,383 | 240,061 | 0.24% | 주식 |
| BloombergSen Inc. | $93,160,317 | 238,940 | 0.24% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $92,247,974 | 236,600 | 0.23% | 풋 옵션 |
| Brandywine Global Investment Management, LLC | $89,380,814 | 191,451 | 0.23% | 주식 |
| BANK OF AMERICA CORP /DE/ | $89,069,981 | 228,449 | 0.23% | 주식 |
| NEUBERGER BERMAN GROUP LLC | $85,926,216 | 220,386 | 0.22% | 주식 |
| MILFORD FUNDS LTD | $82,165,029 | 210,739 | 0.21% | 주식 |
| Bridgewater Associates, LP | $79,227,208 | 203,204 | 0.20% | 주식 |
| Prana Capital Management, LP | $75,552,494 | 193,779 | 0.19% | 주식 |
| DANSKE BANK A/S | $73,238,497 | 187,844 | 0.19% | 주식 |
| FRANKLIN RESOURCES INC | $70,965,828 | 182,015 | 0.18% | 주식 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $70,445,715 | 180,681 | 0.18% | 주식 |
| Quantinno Capital Management LP | $70,407,055 | 180,581 | 0.18% | 주식 |
| ARGENT CAPITAL MANAGEMENT LLC | $69,149,681 | 177,357 | 0.18% | 주식 |
| Retirement Systems of Alabama | $68,081,812 | 174,618 | 0.17% | 주식 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $66,167,842 | 169,709 | 0.17% | 주식 |
| BNP PARIBAS FINANCIAL MARKETS | $64,793,090 | 166,183 | 0.16% | 주식 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $64,665,206 | 165,855 | 0.16% | 주식 |
| HSBC HOLDINGS PLC | $64,431,534 | 165,332 | 0.16% | 주식 |
| AVIVA PLC | $64,264,789 | 164,828 | 0.16% | 주식 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $64,194,533 | 135,649 | 0.16% | 주식 |
| SEB Asset Management AB | $63,257,255 | 162,244 | 0.16% | 주식 |
| TODD ASSET MANAGEMENT LLC | $62,567,208 | 160,474 | 0.16% | 주식 |
| Swedbank AB | $62,528,998 | 160,376 | 0.16% | 주식 |
| W1M Investment Management Ltd | $61,247,490 | 143,647 | 0.16% | 주식 |
| HARRIS ASSOCIATES L P | $60,080,879 | 154,097 | 0.15% | 주식 |
| Ensign Peak Advisors, Inc | $58,372,381 | 149,715 | 0.15% | 주식 |
| NEW YORK STATE COMMON RETIREMENT FUND | $57,747,778 | 148,113 | 0.15% | 주식 |
| CITADEL ADVISORS LLC | $57,235,852 | 146,800 | 0.15% | 풋 옵션 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $57,160,993 | 146,800 | 0.14% | 주식 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $56,512,217 | 144,944 | 0.14% | 주식 |
| Pictet Asset Management Holding SA | $52,147,803 | 133,739 | 0.13% | 주식 |
| VICTORY CAPITAL MANAGEMENT INC | $50,752,761 | 130,172 | 0.13% | 주식 |
| Pentwater Capital Management LP | $50,685,700 | 130,000 | 0.13% | 주식 |
| D. E. Shaw & Co., Inc. | $50,554,307 | 129,663 | 0.13% | 주식 |
| APG Asset Management N.V. | $50,368,550 | 147,699 | 0.13% | 주식 |
| AMF Tjanstepension AB | $50,355,853 | 129,154 | 0.13% | 주식 |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $50,349,225 | 129,137 | 0.13% | 주식 |
| EQUITABLE TRUST CO | $49,147,974 | 126,056 | 0.12% | 주식 |
| ENVESTNET ASSET MANAGEMENT INC | $48,919,124 | 125,469 | 0.12% | 주식 |
| CANADA PENSION PLAN INVESTMENT BOARD | $48,197,812 | 123,619 | 0.12% | 주식 |
| AMERICAN CENTURY COMPANIES INC | $47,460,140 | 121,727 | 0.12% | 주식 |
| OpenArc Corporate Advisory, LLC | $47,210,610 | 121,087 | 0.12% | 주식 |
| L1 Capital International Pty Ltd | $46,121,648 | 118,294 | 0.12% | 주식 |
| FIRST TRUST ADVISORS LP | $44,251,579 | 113,498 | 0.11% | 주식 |
| PFA Pension, Forsikringsaktieselskab | $44,046,098 | 112,971 | 0.11% | 주식 |
| United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund | $43,830,264 | 112,417 | 0.11% | 주식 |
| EP Wealth Advisors, LLC | $43,287,826 | 111,026 | 0.11% | 주식 |
| WOLVERINE TRADING, LLC | $42,597,104 | 101,200 | 0.11% | 콜 옵션 |
| MERCER GLOBAL ADVISORS INC /ADV | $42,302,070 | 108,497 | 0.11% | 주식 |
회사 내부자 91 명의 내부자 · 54 임원 · 31 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| Samuel N Hazen | CEO | 2026년 2월 10일 F | 64,842 | 0 | 7 | $-21,483,290 |
| O'Boyle Michael P | President & CEO - Parallon | 2013년 2월 26일 A | 21,429 | 0 | 0 | $0 |
| Mike A Marks | EVP and CFO | 2026년 5월 7일 G | 46,576 | 0 | 0 | $0 |
| Bill B Rutherford | CFO and EVP | 2024년 2월 16일 F | 22,251 | 0 | 0 | $0 |
| Russell K Harms | CFO - Central Group | 2006년 11월 17일 D | 0 | 0 | 0 | $0 |
| Robert Samuel Hankins JR | CFO-Outpatient Services Group | 2006년 11월 17일 D | 0 | 0 | 0 | $0 |
| Richard J Shallcross | CFO - Western Group | 2006년 11월 17일 D | 0 | 0 | 0 | $0 |
| Jeffrey T Crudele | CFO-Eastern Division | 2005년 7월 1일 F | 13,865 | 0 | 0 | $0 |
| Erol R Akdamar | Group President | 2024년 11월 12일 M | 6,843 | 0 | 0 | $0 |
| Timothy M Mcmanus | Group President | 2024년 7월 31일 M | 27,008 | 0 | 0 | $0 |
| Richard A Hammett | Group President | 2024년 2월 16일 F | 17,936 | 0 | 0 | $0 |
| Charles J Hall | Group President | 2022년 11월 11일 M | 202,443 | 0 | 0 | $0 |
| Bruce A Moore JR | Group President - Service Line | 2022년 11월 11일 S | 30,807 | 0 | 0 | $0 |
| Paul W Rutledge | Group President | 2012년 12월 31일 A | 335,657 | 0 | 0 | $0 |
| Beverly B Wallace | President - Parallon | 2011년 11월 2일 M | 144,714 | 0 | 0 | $0 |
| Charles Robert Evans | President - Eastern Group | 2006년 7월 26일 A | 62,173 | 0 | 0 | $0 |
| Marilyn B Tavenner | President-Outpatient Svcs Grp | 2005년 10월 27일 A | 26,154 | 0 | 0 | $0 |
| Greg Roth | President-Ambulatory Surgery | 2004년 10월 31일 D | 9,029 | 0 | 0 | $0 |
| Jay Grinney | President-Eastern Group | 2004년 5월 7일 D | 24,177 | 0 | 0 | $0 |
| Jon M Foster | EVP and COO | 2026년 2월 10일 F | 23,062 | 0 | 0 | $0 |
| Michael R Mcalevey | EVP & Chief Legal & Admin Off. | 2026년 2월 13일 M | 8,853 | 0 | 2 | $-2,747,520 |
| Jennifer Berres | SVP & Chief Human Res. Officer | 2026년 2월 11일 S | 11,993 | 0 | 2 | $-4,126,932 |
| Christopher F. Wyatt | SVP & Controller | 2026년 2월 11일 S | 44,379 | 0 | 1 | $-2,020,000 |
| Erica Rossitto | SVP & Chief Nurse Executive | 2026년 2월 10일 F | 10,407 | 0 | 0 | $0 |
| Michael S. Cuffe | EVP and Chief Clinical Officer | 2026년 2월 10일 F | 32,080 | 0 | 1 | $-747,135 |
| Sammie S Mosier | SVP & Chief Nurse Executive | 2025년 2월 13일 F | 11,113 | 0 | 0 | $0 |
| Kathleen M Whalen | SVP & Chief Ethics Officer | 2024년 11월 14일 S | 9,454 | 0 | 0 | $0 |
| Phillip G Billington | SVP-Internal Audit Services | 2024년 11월 12일 M | 52,702 | 0 | 0 | $0 |
| Joseph A Sowell III | SVP; Chief Development Officer | 2024년 8월 5일 G | 18,526 | 0 | 0 | $0 |
| Deborah M Reiner | SVP - Mktg. & Communications | 2024년 7월 29일 S | 3,510 | 0 | 0 | $0 |
| Kathryn A. Torres | SVP-Payer Contracting & Align. | 2024년 7월 25일 S | 17,755 | 0 | 0 | $0 |
| Jeffrey E. Cohen | SVP-Government Relations | 2024년 5월 9일 S | 5,185 | 0 | 0 | $0 |
| Chad J Wasserman | SVP and CIO | 2024년 3월 18일 M | 1,576 | 0 | 0 | $0 |
| Martin P. Paslick | SVP and CIO | 2023년 4월 12일 M | 24,643 | 0 | 0 | $0 |
| Jane D. Englebright | SVP and Chief Nursing Officer | 2021년 11월 9일 S | 0 | 0 | 0 | $0 |
| Robert A Waterman | SVP & General Counsel | 2021년 5월 5일 S | 50,062 | 0 | 0 | $0 |
| William J Morrow | SVP - Finance and Treasurer | 2021년 2월 18일 F | 5,578 | 0 | 0 | $0 |
| Sandra L. Morgan | SVP-Provider Relations | 2021년 2월 18일 F | 10,122 | 0 | 0 | $0 |
| Victor L Campbell | SVP-Government Affairs | 2019년 5월 1일 A | 194,145 | 0 | 0 | $0 |
| John M Steele | SVP & Chief Human Res. Officer | 2019년 2월 25일 M | 84,157 | 0 | 0 | $0 |
| Milton R Johnson | Chairman | 2019년 2월 25일 M | 881,823 | 0 | 0 | $0 |
| Ravi S. Chari | SVP-Clinical Excellence | 2018년 2월 25일 M | 7,003 | 0 | 0 | $0 |
| Alan R Yuspeh | SVP & Chief Ethics Officer | 2018년 2월 25일 M | 35,546 | 0 | 0 | $0 |
| Joseph N Steakley | SVP-Internal Audit Services | 2018년 2월 25일 M | 65,199 | 0 | 0 | $0 |
| Jana Joustra Davis | SVP - Mktg. & Corp. Affairs | 2017년 5월 23일 M | 26,378 | 0 | 0 | $0 |
| David Gwin Anderson | SVP - Finance | 2016년 11월 7일 M | 110,167 | 0 | 0 | $0 |
| Donald W Stinnett | SVP & Controller | 2016년 2월 25일 A | 51,965 | 0 | 0 | $0 |
| Noel B Williams | SVP and CIO | 2012년 5월 16일 M | 299,030 | 0 | 0 | $0 |
| Jack O Bovender JR | Chairman | 2009년 10월 6일 A | 188,340 | 0 | 0 | $0 |
| Carl V George | SVP - Development | 2009년 2월 27일 M | 13,092 | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
행동주의자 및 5% 이상 소유자 4 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| Frisco Holding II, Hercules Holding II, Thomas F. Frist, Jr., Thomas F. Frist III, William R. Frist, Patricia F. Elcan | 2026년 2월 10일 | 31.60% | 최초 제출 | — | SEC |
| 2006년 11월 22일 | — | 최초 제출 | — | SEC | |
| Merrill Lynch Bank USA | 2006년 9월 11일 | — | 최초 제출 | — | SEC |
| Frisco, Inc., Frisco Partners, Thomas F. Frist, Jr., Patricia Champion Frist, Patricia Frist Elcan, William Robert Frist, Thomas F. Frist III, Merrill Lynch Professional Clearing Corp., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Merrill Lynch Financial Markets, Inc., Merrill Lynch International, Merrill Lynch & Co., Inc., Merrill Lynch Trust Company, FSB, Citigroup Inc.*, Bank of America Corporation, NB Holdings Corporation, NationsBanc Montgomery Holdings Corporation, Banc of America Securities LLC | 2006년 8월 4일 | — | 최초 제출 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF 보유 현황 207 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| IHF · iShares Trust | 4.67% | 141,320 SH | 2026년 8월 8일 | 일간 |
| BUL · Pacer Funds Trust | 3.91% | 11,437 NS | 2026년 4월 30일 | N-PORT |
| YALL · Tidal Trust I | 3.61% | 9,261 NS | 2026년 5월 31일 | N-PORT |
| BWTG · ETF Opportunities Trust | 3.02% | 1,646 NS | 2026년 5월 31일 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 2.32% | 99,335 SH | 2026년 8월 8일 | 일간 |
| ABIG · EA Series Trust | 2.00% | 2,938 NS | 2026년 5월 29일 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 1.99% | 39,985 NS | 2026년 4월 30일 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.67% | 31,685 SH | 2026년 8월 8일 | 일간 |
| COWZ · Pacer Funds Trust | 1.64% | 688,264 NS | 2026년 4월 30일 | N-PORT |
| QQWZ · Pacer Funds Trust | 1.64% | 1,762 NS | 2026년 4월 30일 | N-PORT |
| FEGE · RBB Fund Trust | 1.46% | 74,706 NS | 2026년 5월 31일 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1.39% | 60,385 SH | 2026년 8월 8일 | 일간 |
| RPG · Invesco Exchange-Traded Fund Trust | 1.30% | 63,448 SH | 2026년 8월 8일 | 일간 |
| TMFE · RBB Fund, Inc. | 1.29% | 2,892 NS | 2026년 5월 31일 | N-PORT |
| AMID · EA Series Trust | 1.23% | 3,402 NS | 2026년 5월 29일 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1.15% | 7,180 NS | 2026년 4월 30일 | N-PORT |
| FMAG · FIDELITY COVINGTON TRUST | 1.12% | 6,544 NS | 2026년 4월 30일 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 1.12% | 73,639 NS | 2026년 4월 30일 | N-PORT |
| SRHQ · Elevation Series Trust | 1.10% | 4,883 NS | 2026년 4월 30일 | N-PORT |
| IYH · iShares Trust | 0.99% | 89,420 SH | 2026년 8월 8일 | 일간 |
| NEAR · iShares U.S. ETF Trust | 0.99% | 48,109,000 SH | 2026년 8월 8일 | 일간 |
| CURE · Direxion Shares ETF Trust | 0.98% | 3,122 NS | 2026년 4월 30일 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.90% | 470,451 SH | 2026년 8월 8일 | 일간 |
| NFRA · FlexShares Trust | 0.88% | 62,176 NS | 2026년 4월 30일 | N-PORT |
| REVS · Columbia ETF Trust I | 0.87% | 5,693 NS | 2026년 4월 30일 | N-PORT |
| RXL · ProShares Trust | 0.86% | 1,632 NS | 2026년 5월 31일 | N-PORT |
| DIVB · iShares Trust | 0.85% | 36,806 SH | 2026년 8월 8일 | 일간 |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0.82% | 24,078,000 | 2026년 8월 8일 | 일간 |
| LSEQ · Harbor ETF Trust | 0.81% | 285 NS | 2026년 4월 30일 | N-PORT |
| IXJ · iShares Trust | 0.80% | 81,465 SH | 2026년 8월 8일 | 일간 |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0.76% | 26,493,000 | 2026년 8월 8일 | 일간 |
| SPVM · Invesco Exchange-Traded Fund Trust | 0.74% | 2,335 SH | 2026년 8월 8일 | 일간 |
| FTC · First Trust Exchange-Traded AlphaDE… | 0.73% | 21,329 NS | 2026년 4월 30일 | N-PORT |
| RFFC · ALPS ETF Trust | 0.68% | 533 NS | 2026년 5월 31일 | N-PORT |
| QUVU · Hartford Funds Exchange-Traded Trust | 0.68% | 2,698 NS | 2026년 4월 30일 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0.67% | 12,075 SH | 2026년 8월 8일 | 일간 |
| VCEB · VANGUARD WORLD FUND | 0.62% | 8,146,000 PA | 2026년 8월 8일 | 일간 |
| FDMO · FIDELITY COVINGTON TRUST | 0.61% | 11,771 NS | 2026년 4월 30일 | N-PORT |
| RECS · Columbia ETF Trust I | 0.58% | 72,768 NS | 2026년 4월 30일 | N-PORT |
| AFLG · First Trust Exchange-Traded Fund VI… | 0.56% | 9,664 NS | 2026년 5월 31일 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0.55% | 11,876 SH | 2026년 8월 8일 | 일간 |
| VLLU · Harbor ETF Trust | 0.54% | 54 NS | 2026년 4월 30일 | N-PORT |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0.53% | 7,404 NS | 2026년 4월 30일 | N-PORT |
| WLDR · Two Roads Shared Trust | 0.51% | 844 NS | 2026년 4월 30일 | N-PORT |
| VALQ · AMERICAN CENTURY ETF TRUST | 0.50% | 4,620 NS | 2026년 5월 31일 | N-PORT |
| AKAF · ETF Series Solutions | 0.50% | 39 NS | 2026년 5월 31일 | N-PORT |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0.50% | 22,679,000 | 2026년 8월 8일 | 일간 |
| ROUS · Lattice Strategies Trust | 0.47% | 6,388 NS | 2026년 4월 30일 | N-PORT |
| VCLT · VANGUARD SCOTTSDALE FUNDS | 0.46% | 54,218,000 PA | 2026년 8월 8일 | 일간 |
| CGGR · Capital Group Growth ETF | 0.45% | 290,273 NS | 2026년 5월 31일 | N-PORT |